ESPR
Esperion Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.18
+0.00%Year over year
Reported trailing growth
- Revenue
- +61.1%
- EBITDA
- +145.1%
- EBIT
- +289.6%
- EPS
- +97.0%
- Free cash flow
- +81.9%
- Operating cash flow
- +81.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +74.8%
- EBITDA
- +743.8%
- EBIT
- +10.8%
- Net income
- +56.2%
- EPS
- +60.7%
- Free cash flow
- +45.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026